Therapeutic Target Identification (using Valid-NEO or others) Science. 2021 Mar5; 371(6533): eabc8697. Targeting a neoantigen derived from a common TP53 mutation. Valid-NEO Science Advances. 2022 Jan 28;8(4):eabj3671. Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy.Valid-NEO Journal for Immunotherapy of Cancer. 2025 Aug 3;13(8):e010099. HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer. Valid-NEO Blood Advances. 2022 Dec 9;7(9):1635–1649. Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT.Valid-NEO Cancer Immunol Res . 2019 Nov;7(11):1748-1754. Direct Detection and Quantification of Neoantigens.Valid-NEO Cancers. 2022 Feb 28;14(5):1243. Valid-NEO: A Multi-Omics Platform for Neoantigen Detection and Quantification from Limited Clinical Samples.Valid-NEO Science Immunology. 2021 Mar 1;6(57):eabd5515. Bispecific antibodies targeting mutant RAS neoantigens.Valid-NEO Biomarker and Liquid Biopsy (i.e. Complete360) Proc Natl Acad Sci U S A. 2011 Feb 8; 108(6):2444-9. Mutant proteins as cancer-specific biomarkers.Testing proceduresLiquid Omics Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13519-13524. Selected reaction monitoring approach for validating peptide biomarkers.Liquid Omics bioRxiv [Preprint]. 2025 May 20:2025.05.15.654311. doi: 10.1101/2025.05.15.654311.Liquid Omics Cell. 2025 Aug 7;188(16):4225-4238.e12. doi: 10.1016/j.cell.2025.05.038. Wang X, et al. An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis.Liquid Omics Nature Communications. 2025 Jan 30;16(1):1191. doi: 10.1038/s41467-025-56492-8. Jia Y, et al. Mitochondrial KMT9 methylates DLAT to control pyruvate dehydrogenase activity and prostate cancer growth.Biomarkers Science [Accepted]. 2026 March Severe Obesity in Human HFpEF Alters Contractile Protein Function and Organization.Biomarkers
